LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. Our leadership is composed of individuals with extensive experience in the discovery, development, and commercialization of neuropsychiatric therapeutics.
Scientific Advisory Board
We are advised by renowned experts in treating psychiatric diseases.
John M. Kane, M.D., is the Chairman of our Scientific Advisory Board and the Principal Investigator of our Phase 2 study (LB-102-003). Dr. Kane served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years and Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine for 12 years. He is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Co-Director of the Institute for Behavioral Science at the Feinstein Institutes for Medical Research. He earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society. He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 900 peer-reviewed papers and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work.
Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society. He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 900 peer-reviewed papers and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work.
Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.
Christoph U. Correll, M.D., has been a member of the Company’s Scientific Advisory Board since May 2016. Dr. Correll is professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, and professor and chair of the department of child and adolescent psychiatry, Charite University, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.
Dr. Correll’s research and clinical work focus on the identification, characterization and treatment of adults and youths with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology, clinical trials, epidemiology, meta-analyses and the risk–benefit evaluation of psychotropic medications, including the interface between physical and mental health.
Dr. Correll has authored over 900 journal articles that have been cited more than 78,000 times. He has served on several expert consensus and guideline panels on the use of antipsychotics and on the overall assessment and management of people with several severe mental disorders, and has received over 40 national and international research awards. Since 2014, the year of inception of this metric, he has been listed each year by Clarivate/Web of Science in as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
Dr. Correll’s research and clinical work focus on the identification, characterization and treatment of adults and youths with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology, clinical trials, epidemiology, meta-analyses and the risk–benefit evaluation of psychotropic medications, including the interface between physical and mental health.
Dr. Correll has authored over 900 journal articles that have been cited more than 78,000 times. He has served on several expert consensus and guideline panels on the use of antipsychotics and on the overall assessment and management of people with several severe mental disorders, and has received over 40 national and international research awards. Since 2014, the year of inception of this metric, he has been listed each year by Clarivate/Web of Science in as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
Maurizio Fava, M.D., is the Psychiatrist-In-Chief, Department of Psychiatry and Director, Division of Clinical Research at Mass General Research Institute. Dr. Fava is also the Executive Director of the Clinical Trials Network & Institute, as well as the Associate Dean for Clinical & Translational Research and Slater Family Professor of Psychiatry at Harvard Medical School.
Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology. He completed residency training in psychiatry at Mass General. He founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry.
Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $95 million. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.
Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts.
Source: https://www.massgeneral.org/doctors/16784/maurizio-fava
Luca Pani, M.D., is Professor, Clinical Psychiatry, at the University of Miami’s Miller School of Medicine.
After graduating in medicine and surgery and specializing in psychiatry, he completed his training overseas with a postdoctoral fellowship in neurobiology and neuropharmacology at the University of Illinois at Chicago (from 1990 to 1992), and then took a position as an associate professor at Georgetown University in Washington (from 1993 to 1994). He then returned to Italy where he continued his research activity both at the University of Cagliari and at the National Research Council (CNR) in Cagliari, reaching the position of Research Director in 2001, without ever breaking the link with the USA, where in fact he moved his permanent residence in August 2010 and where he became, in 2011, Voluntary Professor at the University of Miami.
He has been a research manager at CNR since 2002 and, from the same year until 2010, he was President and CEO of Neuroscience PharmaNess Scarl, a consortium owned by the University of Cagliari and the CNR, dedicated to the preclinical evaluation of new active pharmacological principles. In the same period he is also Head of the Operational Unit of the Institute of Biomedical Technologies, first, and the Institute of Translational Pharmacology, then, of the CNR site located at the Science and Technology Park of Sardinia, at Pula (Cagliari).
In 2008 he was the main creator (and one of the founders) of the first company with entirely public capital (Autonomous Region of Sardinia) dedicated to Translational Pharmacology of Phase-1 studies for the discovery of new drugs.
His unique expertise in the preclinical evaluation of new active ingredients combined with a long clinical experience as a specialist in mood disorders, anxiety, and depression earned him the appointment, in 2010, as Permanent Representative for Italy at the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency (EMA), a position that was reconfirmed in 2013 and 2016. From November 2011 to October 2016 he served as Director-General of the Italian Medicines Agency (AIFA). At EMA he is also a permanent member of the Scientific Advice Working Party and participates in the Central Nervous System Working Group (CNSWG). From 2013 to 2016, Luca Pani is the Chair of the Management Board Telematics Committee (MBTC) and of the European Risk Management Strategy Group (ERMS). Since January 2017 he becomes the Chief Scientific Officer at EDRA-LSWR, Publishing Company in Milan and since June of the same year, he holds the same position at Inpeco, an Italian-Swiss company leader in mechatronics and laboratory automation in the medical field based in Novazzano, Switzerland from which he resigned at the end of 2021. At the end of 2017, Luca Pani accepts the role of Executive Advisor of Neurocog Trial based in Durham in North Caroline, USA. One year later, in October of 2018, NeuroCog Trials becomes VeraSci and in July 2021 VeraSci is acquired by WCG while Luca retains his role of VP for Regulatory Strategy and Market Access Innovation.
